The tablet and the injection share an active ingredient but not a registered use. It is worth being clear on the difference before you see a doctor.
✓ 2019 — First GLP-1 tablet approved. US regulators approved oral semaglutide for adults with type 2 diabetes, the first GLP-1 medicine available as a tablet. (1)
✓ Singapore — Registered for type 2 diabetes. Here, the tablet is registered to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. (5)
✓ Late 2025 — Higher-strength tablet approved overseas for weight. US regulators approved a 25 mg daily semaglutide tablet for chronic weight management, based on the OASIS trials. It is a different product from the diabetes tablet. (4)
▸ Weight management — Not registered in Singapore. The diabetes tablet is not registered here for weight loss. Using it for weight alone would be off-label, and is a decision for a doctor after a full assessment. (5)